Strategic Acquisition of BioNX Closed
Acquisition of BioNX closed in mid‑April; BioNX adds 6 commercial regenerative biomaterial products, positioning the company in a fast‑growing healthcare segment and providing an expanded commercial footprint.
NexGel Inc
· NXGL
May 15th, 2026
Summary
- Earnings Call Date:
- 2026-05-15
- Change Since:
- +5.88%
- Next Earnings Date:
- 2026-08-18
Earnings Call Sentiment
PositiveThe call emphasized a transformational acquisition (BioNX), strategic financing and partnership with Sequence LifeScience, strengthened leadership, a commercial product portfolio in ~500 hospitals, and pro forma projections to triple revenue to ~$35M and be accretive — all significant positives. Offsetting these are near‑term operational and liquidity pressures: Q1 revenue declined ~5.7% YoY, cash on hand fell to $1.8M, SG&A is elevated, and some legacy consumer products and key customer relationships have underperformed. Management reported early signs of recovery and initial BioNX sales beginning in Q2, but timing and execution risk remain notable.
Company Guidance
The company guided that the BioNX acquisition is expected to be transformative: on a pro forma basis it should approximately triple annual revenue to roughly $35 million and be “immediately accretive to profitability” upon closing; BioNX revenue will begin to be recognized for about half of Q2. Key near‑term financials and capital metrics cited were Q1 revenue of $2.65M (vs. $2.81M year‑ago), cash and restricted cash of ~$2.1M as of 3/31/2026 with $1.8M on hand today, and $13.8M total capital raised (comprised of $8.8M cash and a $5.0M convertible note to Cellularity), while Sequence LifeScience led financing with a $5.5M investment. Operational and pipeline metrics included a BioNX portfolio of 6 commercial regenerative products already approved in ~500 U.S. hospitals, three 510(k) devices in development representing about $4.6M of invested paid‑in capital targeted for commercialization in 2027, 2026 and (as stated) 2020, and an incremental operating run‑rate of roughly $500K per month (salaries, marketing, commissions) for the expanded commercial/R&D footprint.
Pro Forma Revenue Projection and Accretion
Management expects the transaction to approximately triple annual revenue to roughly $35 million on a pro forma basis and to be "immediately accretive to profitability" upon closing (company guidance/projection).
Material Financing and Strategic Partner
Company raised $13.8 million total (comprised of $8.8M received in cash and a $5.0M convertible note) to fund the acquisition and working capital. Sequence LifeScience led financing for BioNX with a $5.5M investment and has joined the company’s board, bringing manufacturing, product development, and distribution capabilities.
Commercial Footprint and Pipeline Investment
BioNX products are commercial stage and approved in approximately 500 U.S. hospitals. The company has 3 510(k) devices in development with approximately $4.6M of invested paid‑in capital targeted for commercialization (years cited in the call).
Management and Commercial Team Strengthening
Appointed Dave Hazard as VP of Sales for BioNX Surgical and added Ian Blackman as CFO; Sequence LifeScience executives Brian Keeser and Kevin Harris joined the board—strengthening commercial, scientific, and financial leadership.
Early Signs of Revenue Recovery and Initial BioNX Sales
Management reported Silly George sales 'normalize and recover' in April and expects to recognize roughly half of BioNX revenues in Q2 (first quarter did not include any BioNX revenue).
Positive Clinical/Study Result for Laser Hair Removal Product
Published study (sponsored by partner Innovative Optics) showed strong outcomes: ~90% reduction in plume, reduced pain as a secondary endpoint, and ~70% efficacy — a commercial opportunity via partner distribution relationships with laser manufacturers.
Operator
A member of our team will be happy to help. Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to NEXGEL's Shareholder Update Conference Call. I will now turn the call over to Valter Pinto, Managing Director of KCSA Strategic communications for introductions. Please go ahead.
Valter Pinto
Thank you, operator. Good afternoon, and welcome, everyone, to NEXGEL's shareholder update conference call. I am joined today by Adam R. Levy, Chief Executive Officer. Before we begin, I would like to remind everyone that statements made during today's conference call may be deemed forward looking statements within the meaning of the safe harbor of the Private Securities Litigation Reform Act of 2 thousand. And actual results may differ materially due to a variety of risks, uncertainties, and other factors. For a detailed discussion of some of the ongoing risks and uncertainties in the company's business, I refer you to our filings with the SEC filed periodically. Company disclaims any intention or obligation to update or revise any forward looking statements whether as a result of new information, future events or otherwise.
Unless otherwise required by law. With that, it is my pleasure to turn the call over to Mr. Adam R. Levy, Adam, please go ahead.
Adam R. Levy
Thank you, Valter, and thank you, everyone, for joining us today. On today's call, I would like to provide an overview of our first quarter 20 financial results and bring everyone up to speed on the progress we have made on the integration of the acquisition we recently closed in mid April. Starting wi...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free